Key result
Older age in STEMI is linked to ~11% one-month mortality in the oldest patients.
Why the study?
The risks of no/slow-reflow phenomena and treatment outcomes in STEMI patients across different age groups were not well characterized.
How do treatment outcomes and mortality differ across age groups in STEMI patients with no/slow-reflow phenomenon undergoing PCI?
Cohort (n=535)
How do treatment outcomes and mortality differ across age groups in STEMI patients with no/slow-reflow phenomenon undergoing PCI?
In STEMI patients with no/slow-reflow phenomenon, older age is associated with significantly higher 30-day mortality, longer PCI times, and the need for more coronary stents.
Answers are grounded in this paper and cite their sources.
Supports age-stratified risk assessment in no-reflow STEMI; leaves open whether targeted interventions reduce elderly mortality.
Objective: To assess the risks of no/slow-reflow phenomena and treatment outcomes in patients with ST-segment elevation myocardial infarction (STEMI) from different age groups. Materials and methods: We analyzed treatment outcomes of 535 STEMI patients who were divided into 4 groups based on their age: 33 patients younger than 44 years (group 1), 209 patients aged 45 to 59 years (group 2), 247 patients aged 60 to 74 years (group 3), and 46 patients aged 75 to 80 years (group 4). Results: Our study revealed that among the young people STEMI is more often found in men, whereas in the older population the number of women increases accounting for 37% (compare with 3% among the young patients). It was also shown that with age, statistically significantly more coronary stents (P = .009, KruskalWallis test) are needed to repair an infarct-related coronary artery lesion. The time required to perform a percutaneous coronary intervention was statistically significantly higher in the older adults than in the young patients (P = .022, Kruskal-Wallis test). Conclusions: Our study found that the frequency of deaths was higher in STEMI patients from the older age groups (9.30% and 10.90%), whereas in the young patients, no deaths were registered during the 30-day followup. In the middleaged patients, mortality accounted for 3.3%. The reported differences were statistically significant (P = .016, Pearson’s χ2). The analysis of overall survival based on the age group revealed statistically significant differences (likelihood ratio test, P = .006).
No takes yet. Share an insight, caveat, or question.
Sazanov et al. (2023) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=535). Older age vs. Younger age was evaluated on 30-day mortality (p=0.016). Older age in STEMI patients was associated with higher 30-day mortality, reaching 10.90% in patients aged 75-80 years compared to 0% in those under 44 years.
Synapse has enriched 10 related papers. Consider them for comparative context: